News | November 10, 2022
LANXESS to showcase Biosecurity Solutions at EuroTier 2022
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Brazil has the 4th largest pet market in the world with an estimated market size of BRL 1.8 billion, growing annually at 16%
The facility will cater to the storage, handling and transportation of pharma, dairy products seafood among others
Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry
The total cost of the project is estimated at Rs 30 crore
Subscribe To Our Newsletter & Stay Updated
